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Key messages 
What is already known about this subject?
 ► MCTD is a rare autoimmune disorder character-
ised by features of other connective tissue diseas-
es such as systemic sclerosis, systemic lupus, and 
polymyositis.
 ► There is non-consensus with regards to its classifi-
cation criteria, diagnoses and standard of care.
What does this study add?
 ► This work highlights the absence of clinical practice 
guidelines in the matter of MCTD.
How might this impact on clinical practice?
 ► it does not impact on clinical practice since there 
is no CPG.
AbstrAct
Mixed connective tissue disease (MCTD) is a complex 
overlap disease with features of different autoimmune 
connective tissue diseases (CTDs) namely systemic 
sclerosis, poly/dermatomyositis and systemic lupus 
erythematous in patients with antibodies targeting the U1 
small nuclear ribonucleoprotein particle. in this narrative 
review, we summarise the results of a systematic literature 
research which was performed as part of the european 
Reference Network on Rare and Complex Connective 
Tissue and Musculoskeletal Diseases project, aimed at 
evaluating existing clinical practice guidelines (CPGs) or 
recommendations. Since no specific CPGs on MCTD were 
found, other CPGs developed for other CTDs were taken 
into consideration in order to discuss what can be applied 
to MCTD even if designed for other diseases. Three major 
objectives were proposed for the future development 
of CPGs: MCTD diagnosis (diagnostic criteria), MCTD 
initial and follow-up evaluations, MCTD treatment. early 
diagnosis, epidemiological data, assessment of burden 
of disease and QOL aspects are among the unmet needs 
identified by patients.
InTroduCTIon
Mixed connective tissue disease (MCTD) was 
initially described by Sharp et al.1 MCTD was 
first reported as a mild overlap disease with 
features of different autoimmune connec-
tive tissue diseases (CTDs) namely systemic 
sclerosis, poly/dermatomyositis and systemic 
lupus erythematous in patients with anti-
bodies targeting the U1 small nuclear ribonu-
cleoprotein particle (U1 snRNP).
Since the initial description, the definition 
as an independent clinical entity has been 
discussed, especially since patients with U1 
snRNP may meet the classification criteria of 
other ‘defined’ CTDs in the course of time.2 3 
Also, the initial description by Sharp of MCTD 
as benign disease without organ involvement 
and with prompt response to low-dose gluco-
corticoids4 has not been confirmed in all 
studies. In addition, there are no generally 
accepted classification criteria.5 Nevertheless, 
some particularities, for example, pulmonary 
disease, point to an independent disease 
pattern.
Clinical practice guidelines (CPGs) are 
defined as ‘systematically developed state-
ments to assist practitioner and patient deci-
sions about healthcare for specific clinical 
circumstances’2 and are made to optimise 
patient care. With regard to CTDs, CPGs should 
be based on medical high-level evidence and 
integrate as many themes as possible of each 
CTD, that is, diagnosis, patients management, 
treatment, prognosis and complications. In 
that matter, the European Reference Network 
on Rare and Complex Connective Tissue and 
Musculoskeletal Diseases (ERN ReCONNET) 
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launched a cooperative effort to review the existing CPGs 
on CTDs.
The objective of this review is to identify and evaluate 
the available CPGs providing specific evidencebased 
medicine (EBM) recommendations for MCTD.
MeTHods
source and search strategy
We carried out a systematic search in PubMed and 
EMBASE based on controlled terms (MeSH and Emtree) 
and keywords of the disease and publication type (CPGs). 
We reviewed all the published articles in order to identify 
existing CPGs on diagnosis, monitoring and treatment, 
according to the Institute of Medicine 20113 definition 
(CPGs are statements that include recommendations 
intended to optimise patient care that are informed by 
a systematic review of evidence and an assessment of the 
benefits and harms of alternative care options3).
The disease coordinator of the ERN-ReCONNET for 
MCTD has assigned the work on CPGs to the health-
care providers (HCPs) involved. Moreover, in order to 
implement the list of guidelines provided by MEDLINE 
and Embase search, the group also performed a hand 
search. A first screening among papers included in the 
final list (systematic search+hand search) based on title 
and abstract selected EBM guidelines to be assessed. A 
general assessment of the CPGs has been performed 
following the Appraisal of Guidelines for Research and 
Evaluation (AGREE) II tool checklist, not for formal 
appraisal but only to inform discussion.4–6 A discussion 
group was set for the evaluation of the existing CPGs and 
to identify the unmet needs.
summary of the search strategy
MEDLINE (PubMed): (“mixed connective tissue 
disease”[MeSH Terms] OR (“mixed”[All Fields] AND 
“connective”[All Fields] AND “tissue”[All Fields] AND 
“disease”[All Fields]) OR “mixed connective tissue 
disease”[All Fields]) OR “sharp syndrome”[all fields] 
AND (“Practice Guideline”[Publication Type] OR 
“Practice Guidelines As Topic”[MeSH Terms] OR Prac-
tice Guideline[Publication Type] OR “Practice Guide-
line”[Text Word] OR “Practice Guidelines”[Text Word] 
OR “Guideline”[Publication Type] OR “Guidelines As 
Topic”[MeSH Terms] OR Guideline[Publication Type] 
OR “Guideline”[Text Word] OR “Guidelines”[Text 
Word] OR “Consensus Development Conference”[Pub-
lication Type] OR “Consensus Development Confer-
ences As Topic”[MeSH Terms] OR “Consensus”[MeSH 
Terms] OR “Consensus”[Text Word] OR “Recommen-
dation”[Text Word] OR “Recommendations”[Text 
Word] OR “Best Practice”[Text Word] OR “Best Prac-
tices”[Text Word]). Embase: ('mixed connective tissue 
disease'/exp OR 'connective tissue disease, mixed' OR 
'mctd' OR 'mixed collagen disease' OR 'mixed connec-
tive tissue disease' OR 'mixed connective tissue disorder' 
OR 'sharp syndrome'/exp) AND ('practice guideline'/
exp OR ‘practice guideline’ OR ‘practice guidelines’/
exp OR ‘practice guidelines’ OR 'clinical practice guide-
line'/exp OR ‘clinical practice guideline’ OR ‘clinical 
practice guidelines’/exp OR ‘clinical practice guide-
lines’ OR 'clinical practice guidelines as topic'/exp OR 
‘clinical practice guidelines as topic’ OR ‘guideline'/
exp OR ‘guideline’ OR ‘guidelines’/exp OR ‘guidelines’ 
OR 'guidelines as topic'/exp OR ‘guidelines as topic’ 
OR ‘consensus development’/exp OR ‘consensus devel-
opment’ OR ‘consensus development conference’/exp 
OR ‘consensus development conference’ OR ‘consensus 
development conferences’/exp OR ‘consensus develop-
ment conferences’ OR ‘consensus development confer-
ences as topic’/exp OR ‘consensus development confer-
ences as topic’ OR ‘consensus’/exp OR ‘consensus’ 
OR ‘recommendation’ OR ‘recommendations’) AND 
embase]/lim NOT [medline]/lim
state of the art on CPGs
Absence of specific recommendations/guidelines for MCTD
The state of the art on CPGs in MCTD is presented in 
figure 1. A systematic Embase/MEDLINE search identi-
fies 124 references to be screened and analysed by the 
ERN ReCONNET MCTD group. After screening and full-
text analysis, five references were selected.7–11 After final 
evaluation, no reference was selected as specific CPG for 
MCTD.
Combined recommendations
Although there was no specific CPG on MCTD, the 
ERN-ReCONNET MCTD group selected five references 
that could be used in the context of MCTD. These refer-
ences were common to other CTD such as systemic scle-
rosis or vasculitis and included recommendations for the 
testing of anti-Sm and anti-RNP antibodies,7 for screening 
pulmonary arterial hypertension,8 for the assessment of 
autoantibodies to cellular antigens referred to as antinu-
clear antibodies,9 for the management of skin ulcers,10 
and for using cardiovascular MR.11
unmet needs
This is the first review providing an overview of currently 
available CPGs for MCTD. We did not identify specific 
CPGs addressing important issues in MCTD. Efficient 
and effective guidelines improve patient care and help 
medical practice and decision-making.12 Therefore, the 
ERN-ReCONNET MCTD group agrees on the general 
need for specific recommendations for MCTD. To 
prioritise what should be done in the matter of MCTD, 
three major objectives were proposed for CPGs future 
development:
1. CPGs on MCTD diagnosis (diagnostic criteria): 
Although different sets of clinical criteria have been 
proposed, there is no consensus about the most accu-
rate one.5 MCTD often resembles several conditions 
and yet can easily be misdiagnosed by numerous rheu-
matic conditions including systemic sclerosis, rheuma-
toid arthritis or so-called overlap syndromes. Without 
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Figure 1 Flow diagram of the systematic literature search on mixed connective tissue disease (MCTD) clinical practice 
guidelines.
a standardised and acknowledged set of criteria, an 
agreement regarding MCTD existence and disease 
CPGs is not possible. Moreover, such classification cri-
teria would facilitate the establishment of registers to 
collect a meaningful number of patients with MCTD 
to evaluate the course and prognosis. The classifica-
tion criteria would also enable to evaluate the role of 
biomarkers, specifically the potential diagnostic/prog-
nostic role of antibodies targeting U1 snRNP and/or in 
combination with the detection of autoantibodies that 
could earlier characterise more defined CTDs such as 
anti-SCL70, anti-CCP, anti-Jo1, antiSm, anti-ds-DNA-as-
sociated entities for defining early progression.
2. CPGs on MCTD initial and follow-up evaluations: At 
present, the initial approach, the type and the frequen-
cy of follow-up assessments of patients with MCTD are 
often handled very differently or performed according 
to the management of other rheumatic diseases. On one 
hand, MCTD is described as a potentially mild and often 
treatable condition.13 On the other hand, the disease is 
incurable and can be deleterious or even life-threaten-
ing with development of pulmonary, kidney, gastrointes-
tinal and central nervous system involvement. Here, ear-
ly and targeted intervention will definitively be associat-
ed with a better outcome. The worst prognosis and high 
mortality are associated with the presence of pulmonary 
disease.14 15 To improve management, it would certainly 
be helpful to develop and validate a (composite) disease 
activity score for MCTD that takes into account all rele-
vant signs and symptoms.16 Agreement on the frequency 
of follow-up assessments during the course of disease on 
the basis of guidelines would facilitate the management 
of patients for clinicians.
3. CPGs on MCTD treatment: There is no agreement 
about the initial or long-term treatment of MCTD, es-
pecially on the usefulness of low-dose glucocorticoids, 
antimalaria and immunosuppressive therapies in vari-
ous clinical situations.17 To date, there has been no ran-
domised controlled trial in MCTD. Usually, patients with 
MCTD are treated based on similarities with other CTDs 
or based on organ-based management.17 Classification 
criteria would therefore also enable to perform clinical 
trials on therapeutic interventions. In addition, the man-
agement of comorbidities (such as osteoporosis, athero-
sclerosis, etc) and specific situations (such as pregnancy, 
family planning, etc) should be addressed. Overall, the 
ERN-ReCONNET MCTD group agrees on the need for 
evidence-based CPGs on MCTD treatment. Such guide-
lines undoubtedly require careful data collection from 
a larger number of patients and collaboration between 
experts and registers from different countries.
Last but not the least, CPGs on MCTD should also take 
into account patients’ point of view in order to improve 
patients’ daily quality of care and life. Patient-reported 
outcomes for patients with MCTD should therefore be 
developed and evaluated.
Patients’ unmet needs
This paragraph intends to highlight the unmet needs of 
the MCTD community. The content of this paragraph 
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has been realised by the ERN ReCONNET European 
Patient Advocacy Group that carefully collected the 
voices and the points of view of the whole European 
community of the disease they represent.
Early diagnosis is the primal need for patients with 
MCTD as it often takes a long time to establish the 
diagnosis. Besides that, when a diagnosis is finally 
made, patients are traditionally vaguely told that they 
have ‘some kind of’ rheumatic disease or autoimmune 
disease which clearly does not help understanding what 
is wrong with them and what they are expected to face 
during the lifelong course of the disease. The under-
standing how this disease develops and what outcomes 
are realistic for these patients, is essential.
Furthermore, prevalence of the disease is not well 
defined, and patients and doctors have no precise infor-
mation on the number of MCTD cases at present. Even-
tually, the European Reference Networks will be able to 
help somehow with the most fundamental measure of the 
burden of the disease to plan appropriately for patient 
healthcare needs. Also, there’s a lack of knowledge 
regarding this disease among physicians as patients often 
feel that they do not know how to address the reported 
symptoms.
Life style and its impact in patients quality of life 
(QOL) is often disregarded, thus the need to measure 
it or understand if it is ever measured would be useful 
to build evidence-based patient-focused guidelines on 
lifestyle issues. There is also a need for a more holistic 
approach to disease management, as doctors may be 
treating symptoms and organ to organ, while overlooking 
the individual beyond the patient. Patient education may 
also contribute to improve QOL.
In addition, pain management and fatigue are huge 
challenge, as pain is still treated insufficiently, and fatigue 
is still inadequately assessed. Non-pharmacological 
approaches and specific programme, such as exercise, 
patient education, psychological support or emotional 
burden management, are needed.
Treatment options are limited to hydroxychloroquine, 
corticosteroids and immunosuppressive drugs, so there 
is also a need for alternative treatments with less side 
effects.
Information and awareness are undoubtfully very 
important unmet needs among all stakeholders involved: 
HCPs, public, employers, families, care givers and 
patients. Furthermore, information on available clinical 
trials is missing so there is definitely a gap to fill.
Last but not least , tax exemption on access to care 
needs reflection, as we need to understand how it works 
in different European countries.
ConClusIons
This review highlights the absence of specific CPG on 
MCTD. There is a need for high-quality evidence-based 
guidelines to assist practitioner and patient decisions 
about MCTD healthcare. Further CPGs should focus on 
MCTD diagnosis, evaluations, treatment and patients’ 
needs. International registries are particularly important 
to collect solid data that can serve as input for CPGs.
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